<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312673</article-id>
      <article-id pub-id-type="pmc">4540507</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153408</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Dapsone in the treatment of pemphigus vulgaris: adverse effects and its
importance as a corticosteroid sparing agent<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Quaresma</surname>
            <given-names>Maria Vict&#xF3;ria</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bernardes Filho</surname>
            <given-names>Fred</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hezel</surname>
            <given-names>Jana&#xED;na</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peretti</surname>
            <given-names>Murilo Calvo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kac</surname>
            <given-names>Bernard Kawa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Azulay-Abulafia</surname>
            <given-names>Luna</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Instituto de Dermatologia Professor Rubem David Azulay-
Santa Casa da Miseric&#xF3;rdia do Rio de Janeiro (IDPRDA-SCMRJ) - Rio de Janeiro (RJ),
Brazil.</aff>
      <aff id="aff02"><label>2</label>Universidade do Estado do Rio de Janeiro (UERJ) - Rio de
Janeiro (RJ), Brazil.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Maria Vict&#xF3;ria Quaresma, Alameda Itu, 1030/ 9B,
Jardim Paulista, 01421-001 - S&#xE3;o Paulo - SP, Brazil. E-mail:
<email>mavi@mavictoria.com.br</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>51</fpage>
      <lpage>54</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>4</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Pemphigus vulgaris is an autoimmune disease characterized by suprabasal blisters with
acantholysis, which has a fatal course in a large number of untreated patients.
Systemic corticosteroid therapy is considered first-line therapy. Adjuvant treatment
with the goal of sparing corticosteroids include, among others, dapsone. This drug is
not without side effects and its use requires clinical and laboratory control. We
present a patient with PV initially managed with suboptimal dose of prednisone,
evolving into drug-induced hepatitis after introduction of dapsone.</p>
      </abstract>
      <kwd-group>
        <kwd>Dapsone</kwd>
        <kwd>Hepatitis</kwd>
        <kwd>Pemphigus</kwd>
        <kwd>Prednisone</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Pemphigus vulgaris (PV) is an autoimmune disease characterized by blisters that may
occur in the mucosa or in other areas of the skin. The characteristic histopathological
finding of PV are suprabasal blisters with acantholysis.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Glucocorticoids are considered the first-line treatment
and are used to reduce the synthesis of autoantibodies. The addition of a second-line
therapy is indicated to increase the efficacy and reduce collateral effects of
corticotherapy, as well as manage relapses during its gradual withdrawal.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> The adjuvant therapy includes
azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil, intravenous
immunoglobulin and dapsone.<sup><xref rid="r03" ref-type="bibr">3</xref></sup> A patient
with PV is presented, initially treated with a subdose of systemic corticotherapy which
evolved to drug-induced hepatitis after introduction of dapsone.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Female patient of african-descent, 50 years old, came to the outpatient clinic
complaining of a single five-month-old bullous lesion in the oral mucosa, which evolved
to erosion and onset of similar cutaneous lesions in other sites. At the examination,
ulcerated crusty lesions were found on the face, scalp, trunk, back and upper limbs,
some with honey-colored crusts.</p>
      <p>She had been previously treated at another clinic with topical antifungals without
improvement, followed by prednisone 20mg/day with slight improvement, which after four
months was associated with dapsone 100mg/day as adjuvant therapy.</p>
      <p>At our service, under the diagnostic hypothesis of PV, we performed the
histopathological study which showed inflammatory suprabasal acantholytic bullous
dermatitis with involvement of pilosebaceous follicle, compatible with PV (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>). Our option was to increase prednisone to 80mg/day, with gradual reduction
after clinical improvement.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Pemphigus vulgaris. Histopathological examination showing inflammatory suprabasal
acantholytic bullous dermatitis with involvement of pilosebaceous follicle
(Hematoxylin-eosin, 40x)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0051-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Pemphigus vulgaris. Detail of histopathological examination: formation of
suprabasal acantholytic blister (Hematoxylin-eosin, 100x)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0051-g02"/>
      </fig>
      <p>Two weeks after starting therapy with prednisone in its immunosuppression dose and six
weeks taking dapsone, the patient reported clinical improvement and denied onset of new
lesions. Laboratory control revealed elevation of glutamic oxaloacetic transaminase (GOT
40 U/L) glutamic-pyruvic transaminase (GPT 76 U/L), gamma-glutamyl transferase (GGT 151
U/L) and alkaline phosphatase (ALP 117 U/L), in addition to leukocytosis (17.300/mm3);
dapsone was suspended. The following week, she returned complaining of itching, dark
urine, acholic feces and jaundice when new control showed significant elevation of
aminotransferases (AST 410 U/L, ALT 622 U/L), bile canalicular enzymes (ALP 361 U/L GGT
1265 U/L), direct bilirubin (BD 4.0 mg/dl) and indirect bilirubin (BI 3.7 mg/dl). She
was then hospitalized and serology for viral hepatitis was requested, which resulted
negative. A total abdominal ultrasonography revealed no abnormalities. The blood levels
of liver enzymes and bilirubin during dapsone use and after withdrawal are shown in
<xref ref-type="fig" rid="f03">figures 3</xref> and <xref ref-type="fig" rid="f04">4</xref>.</p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Blood levels of liver enzymes during use of dapsone and after withdrawal</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0051-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Blood levels of bilirubins during use of dapsone and after withdrawal</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0051-g04"/>
      </fig>
      <p>Thirteen weeks after suspension of dapsone, with decreasing doses of corticotherapy
until the current dose of prednisone 30mg/day, the patient presented clinical
improvement: only small ulcerated crusty areas on the scalp and absence of new lesions.
Residual hyperchromic macules were also noted on the face, trunk, back and upper limbs
(<xref ref-type="fig" rid="f05">Figure 5</xref>).</p>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Patient with pemphigus vulgaris after treatment. Residual hyperchromic macules on
the back</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0051-g05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Systemic corticotherapy is essential in the management of pemphiguses. For PV, the
initial dose is 1-2 mg/kg/day. The reduction of the corticoid must be started after
complete remission of the cutaneous condition and about 1-2 weeks without the onset of
new lesions. The dose is reduced by 10mg/week until 30mg/day is achieved and following
that the reduction should be 5-10 mg/month, obtaining the dose of 10mg/day. From this
dose, withdrawal occurs with decrease of 2.5 mg every 1-2 months according to clinical
course of the disease. Treatment may be suspended after 1 year of low daily doses on
alternate days, without the onset of new lesions.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>For PV, dapsone is appropriate as an adjuvant to corticotherapy in the maintenance phase
of the disease.<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> Clinical improvement, in general, happens in 2-3 weeks
from the beginning of treatment, leading to sharp reduction or even corticoid suspension
within 1-3 months. Dapsone acts by diminishing paraminobenzoic acid to folic acid
conversion, preventing the migration of polymorphonuclear cells by inhibiting lysosomal
enzymatic activity, interfering with the leucocitary cytotoxic system or preventing
cellular response to chemotactic stimuli.<sup><xref rid="r07" ref-type="bibr">7</xref></sup> There is evidence of dapsone efficacy (71% to 83.3%) in the adjuvant
treatment with topical or oral corticosteroids in patients with pemphiguses. <sup><xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>Collateral effects of dapsone may be classified into idiosyncratic and dose-dependent.
Among the idiosyncratic ones there is the rare dapsone hypersensitivity syndrome,
characterized by fever, lymphadenopathy, erythematous cutaneous eruptions and
occasionally hepatic involvement. Dose-dependent effects encompass hemolysis and
methemoglobinemia.<sup><xref rid="r07" ref-type="bibr">7</xref></sup> A study in
tertiary centers showed that this drug was the most common cause of acquired
methemoglobinemia, responsible for 42% of the cases.<sup><xref rid="r09" ref-type="bibr">9</xref></sup> Methemoglobinemia is not caused by the drug itself, but by its
metabolite, hydroxylamine.<sup><xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>A link between development of drug-induced hepatitis and dapsone has been suspected.
Complete blood count must be monitored monthly in the first six months of use and renal
and liver function must be verified quarterly for toxicity research. <sup><xref rid="r02" ref-type="bibr">2</xref></sup> The interval between the initiation of
treatment and the onset of hepatitis varies from two to seven weeks. Hepatocellular and
cholestatic reactions may occur, the latest being the most common mechanism of the
lesion and characterized by the elevation of alkaline phosphatase and transaminases. The
hepatocellular lesion is characterized by elevation of transaminases and the lesion
mechanism occurs by hepatotoxicity and hypersensitivity reaction.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> The patient of the present case
developed drug-induced hepatitis with cholestatic pattern by dapsone, due to the time
she started using it, laboratory alterations found and exclusion of other
hepatopathology causes.</p>
      <p>Therefore, in this clinical case, the use of dapsone as corticoid-sparing drug is
reported for PV, a disease of significant morbimortality, and the occurrence of
drug-induced hepatitis by this drug, emphasizing the relevance of laboratory control
during its use, aiming to prevent undesirable collateral effects, deleterious if not
detected early.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Quaresma MV, Bernardes-Filho F, Hezel J,
Peretti MC, Kac BK, Azulay-Abulafi a L. Dapsone in the treatment of pemphigus
vulgaris: adverse effects and their importance as a corticosteroid sparing. An Bras
Dermatol. 2015;90 (3 Suppl 1): S51-4.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work performed at Instituto de Dermatologia Professor Rubem David Azulay - Santa Casa
da Miseric&#xF3;rdia do Rio de Janeiro (IDPRDA-SCMRJ) - Rio de Janeiro (RJ), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Enk</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Knop</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Mycophenolate is effective in the treatment of pemphigus
vulgaris</article-title>
          <source>Arch Dermatol</source>
          <year>1999</year>
          <volume>135</volume>
          <fpage>54</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">9923781</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A practical approach to treating autoimmune bullous disorders with
systemic medications</article-title>
          <source>J Clin Aesthet Dermatol</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>19</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="pmid">20729961</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scully</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Challacombe</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Pemphigus vulgaris: update on etiopathogenesis, oral manifestations,
and management</article-title>
          <source>Crit Rev Oral Biol Med</source>
          <year>2002</year>
          <volume>13</volume>
          <fpage>397</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="pmid">12393759</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cunha</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Barraviera</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune bullous dermatoses</article-title>
          <source>An Bras Dermatol</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>111</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">19503978</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heaphy</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Albrecht</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Werth</surname>
              <given-names>VP</given-names>
            </name>
          </person-group>
          <article-title>Dapsone as a glucocorticoid-sparing agent in maintenance-phase
pemphigus vulgaris</article-title>
          <source>Arch Dermatol</source>
          <year>2005</year>
          <volume>141</volume>
          <fpage>699</fpage>
          <lpage>702</lpage>
          <pub-id pub-id-type="pmid">15967915</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Werth</surname>
              <given-names>VP</given-names>
            </name>
            <name>
              <surname>Fivenson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pandya</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rico</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Albrecht</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multicenter randomized, double-blind, placebo-controlled, clinical
trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus
vulgaris</article-title>
          <source>Arch Dermatol</source>
          <year>2008</year>
          <volume>144</volume>
          <fpage>25</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">18209165</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernab&#xE9;</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Furuse</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Crivelini</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Tratamento do p&#xEA;nfigo vulgar oral com corticosteroides t&#xF3;pico e
sist&#xEA;mico associados a dapsona e pentoxifilina</article-title>
          <source>Rev Odontol UNESP</source>
          <year>2005</year>
          <volume>34</volume>
          <fpage>49</fpage>
          <lpage>55</lpage>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ciarrocca</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>A retrospective study of the management of oral mucous membrane
pemphigoid with dapsone</article-title>
          <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
          <year>1999</year>
          <volume>88</volume>
          <fpage>159</fpage>
          <lpage>163</lpage>
          <pub-id pub-id-type="pmid">10468458</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ash-Bernal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wise</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Acquired methemoglobinemia: a retrospective series of 138 cases at 2
teaching hospitals</article-title>
          <source>Medicine (Baltimore)</source>
          <year>2004</year>
          <volume>83</volume>
          <fpage>265</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="pmid">15342970</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrawal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Agarwalla</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Dapsone hypersensitivity syndrome: a clinicoepidemiological
review</article-title>
          <source>J Dermatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>883</fpage>
          <lpage>889</lpage>
          <pub-id pub-id-type="pmid">16361748</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
